#Mentoring is a brain to pick, an ear to listen and a push in the right direction 🧠👂🏼➡️ best if done over drinks or shopping! Grateful and inspired by Alessandro Gronchi Marco Fiore, MD, FACS, FEBSh Andrea Covelli Dorian Y. García-Ortega MD, MSc,PhD, FACS and many more amazing #surgeons at #CTOS2023, inside and out of the OR 🙌🏻

Save the Date! Next #ASOchat on Nov 29, 6:30pm - Join the Conversation! Special guests and ASO Social Media Comm. Prakash Pandalai MD FACS @scalpelmomma Lana Bijelic David Caba MD,MS,MPH,FACS Hannah McDonald Kurt Schultz Dorian Y. García-Ortega MD, MSc,PhD, FACS Casey J Allen, MD @SohiniKhan Syed A. Ahmad

Q1. To launch our chat—Regarding #omentectomy and #CytoreductiveSurgery, if you omit omentectomy when performing CRS, what are the reasons you do so? #ASOchat

Q2. Dr. Baumgartner and colleagues found that routine #omentectomy led to higher operative time, blood loss, number of visceral resections, and length of stay. Do you believe that omentectomy increases morbidity for #CytoreductiveSurgery? #ASOchat

Q3. Of 43 pts w/residual omentum, 24 (55.8%) recurred, including 9 (20.9%) with omental recurrence. Do you believe that routine omentectomy can help prevent recurrence and improve survival? Is there a role for omentectomy in patients in which a CC0 during CRS can't be achieved?

Q4. Dr Greer’s paper reports a retrospective review of pts with peritoneal mets who underwent #CRS/HIPEC in US 2000-2017 & the effect of area deprivation index (ADI) on OS. What support after CRS/HIPEC does your Ctr offer for health care beyond oncologic care? #ASOchat

Q5. Particularly when it comes to your pts who are at a greater disadvantage in terms of access & resources, how do you identify these pt grps? What kinds of support does your program provide? What kinds of support do you wish your program could provide? #ASOchat

Q6. In this article, pts in high ADI areas had worse OS (5-yr 61.0% v 28.2%). In Cox analysis, high ADI + cancer recurrence, increases in #PeritonealCarcinomatosisIndex (PCI) & incomplete cytoreduction impacted OS. What factors might lead to these #Disparities? #ASOchat

Reunión Anual 2023 de los comités de Investigación, Ética en Investigación y Bioseguridad del Instituto Nacional de Cancerología. ¡Se vienen buenos cambios! Oscar Arrieta Dorian Y. García-Ortega MD, MSc,PhD, FACS

📡 La Dra Claudia Valverde, oncóloga médica de Vall d’Hebron Institute of Oncology (VHIO) 🇪🇸, presidenta de GEIS, nos hablará de tratamiento médico en #sarcoma #retroperitoneal recurrente. No te lo pierdas! 🗓️Jueves 7 marzo, 8pm CDMX 🔹Registro gratuito: us06web.zoom.us/webinar/regist…

Hoy inicia nuestro curso en Bioestadística y Metodología para Cirujanos Oncólogos y Ginecólogos Oncólogos 101 en Instituto Nacional de Cancerología. Ser un cirujano científico es menester en estos tiempos. Dorian Y. García-Ortega MD, MSc,PhD, FACS Hector Martinez Said DocenciaIncan.MX

We did it. 💪🏼 #ESMOSarcomas2024 DocenciaIncan.MX Dorian Y. García-Ortega MD, MSc,PhD, FACS Sociedad Mexicana de Oncología, A.C. Sarcoma European LatinAmerican Network (SELNET) ESMO - Eur. Oncology gaby alamilla

A new 🌟 TARPSWG achievement: solid data on the largest series of WDLPS #retroperitoneal #sarcoma: after Neoadjuvant RT significantly reduced local recurrence rate Vs surgery alone. #STRASS and #STREXIT data are now corroborated. Great job Mark Fairweather! #SSO2024 #plenary

Excellent plenary session talk by Mark Fairweather adding more proof that neoadjuvant RT has a role for primary RP WDLPS ⁦Brigham and Women’s Department of Surgery⁩ ⁦BWH Surgical Oncology⁩ ⁦TARPSWG⁩ #SSO2024

Recuerda que nuestro 42º Congreso Nacional de Oncología y 11º Congreso Internacional, se llevará a cabo del 6 al 9 de noviembre de 2024 en León, Guanajuato. ¡Los esperamos! #SMeO #todosomosmeo #Congreso2024 #Cáncer #oncology #savethedate #Congreso #sociedadmexicanadeoncología

Are #RECIST still the best criteria for assessing #tumor response? Preplanned analysis of ISG 1001 (AI neoad CTx vs histo-tailored neoad CTx in soft tissue #sarcoma) show inverse correlation between response and survival, regardless of RECIST threshold. Italian Sarcoma Group

Primary #pelvic soft tissue #sarcomas (#PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) academic.oup.com/bjs/article/11… Should be separately consider from #retroperitonal sarcoma? SoMe4Surgery PelvEx European Society of Surgical Oncology (ESSO) Society of Surgical Oncology

🏆 Meet our ESSO Lifetime Achievement Awardee - Prof sylvie bonvalot! Join for the award lecture at #ESSO43 🗓️2 October, 10 AM! Read more about the award 👉essoweb.org/awards/24 #sarcoma #patientcare #surgicaloncology #surgicalaward SFCO

🚨Our latest paper evaluating #proteomic signatures with the Sarculator nomogram to predict high-risk #sarcoma patients is out in CancerMedicine! This is a wonderful collaboration with Sandro Pasquali Rosalba Miceli Alessandro Gronchi Istituto Tumori Read more here dx.doi.org/10.1002/cam4.7…

August Issue: Impact of an Online #RiskCalculator for #SentinelNode Positivity on Management of Patients with T1 and T2 #Melanomas Sydney Ch’ng rdcu.be/dRPma Dorian Y. García-Ortega MD, MSc,PhD, FACS Syed A. Ahmad